REGISTERED NUMBER: 06829408 (England and Wales)

Biocity Investments Limited

Unaudited Financial Statements

for the Year Ended 31 December 2024

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

Directors:

G Crocker

S M Hoad

R A O'Boyle

P S Oliver

T J B Reid

Registered office:

Biocity Nottingham

Pennyfoot Street

Nottingham

NG1 1GF

Registered number:

06829408 (England and Wales)

Accountants:

Cooper Parry Advisory Limited

New Derwent House

69-73 Theobalds Road

London

WC1X 8TA

Fixed assets

Investments

4

1,275,549

1,499,403

Current assets

Debtors

5

25,063

16,140

Cash at bank

22,233

35,625

47,296

51,765

Creditors

Amounts falling due within one year

6

3,561

15,048

Net current assets

43,735

36,717

Total assets less current liabilities

1,319,284

1,536,120

Capital and reserves

Called up share capital

7

121,011

121,011

Share premium

819,000

819,000

Retained earnings

379,273

596,109

Shareholders' funds

1,319,284

1,536,120

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 23 September 2025 and were signed on its behalf by:

P S Oliver - Director

1.	Statutory information

Biocity Investments Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	Accounting policies

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Going concern

The financial statements have been prepared on a going concern basis. The directors have reviewed and considered relevant information, including the annual budget and future cash flows in making their assessment.

Related party exemption

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover

Revenue is measured in accordance with the relevant accounting standards. For all contracts, the company determines whether enforceable rights and obligations have been created with the customer and recognises revenue based on the total transaction price as estimated at the contract inception, being the amount which the company expects to be entitled and has present enforceable rights under the contract. Revenue is allocated proportionally across the contract performance obligations and recognised either over time or at a point in time as appropriate.

Revenue included in the Income Statement represents investment income derived from third parties which is recognised on a monthly basis and accrued or deferred as necessary.

Investment Income

Interest income is recognised in profit or loss using the effective interest method.

Turnover

Revenue is measured in accordance with the relevant accounting standards. For all contracts, the company determines whether enforceable rights and obligations have been created with the customer and recognises revenue based on the total transaction price as estimated at the contract inception, being the amount which the company expects to be entitled and has present enforceable rights under the contract. Revenue is allocated proportionally across the contract performance obligations and recognised either over time or at a point in time as appropriate.

Revenue included in the Income Statement represents investment income derived from third parties which is recognised on a monthly basis and accrued or deferred as necessary.

Investment Income

Interest income is recognised in profit or loss using the effective interest method.

Financial instruments

The company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors, creditors, loans from the bank and other third parties, loans to related parties, and investment in ordinary shares.

Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the company operates and generates income.

Valuation of investments

Listed investments

The fair values of quoted investments are based on bid process at the reporting date.

Unlisted investments

Unlisted investments are carried at cost less any provision for impairment.

3.	Employees and directors

The average number of employees during the year was NIL (2023 - NIL).

4.	Fixed asset investments

Cost

Listed investments

Unlisted investments

Convertible Loans

Totals

At 1 January 2024

239,876

1,222,027

37,500

1,499,403

Additions

-

-

-

-

Disposals

-

-

-

-

Revaluations

(11,423

)

-

-

(11,423

)

Impairments

-

(212,431

)

-

(212,431

)

Transfer from listed investments to unlisted investments

(228,453

)

228,453

-

-

At 31 December 2024

-

1,238,049

37,500

1,275,549

Net book value

At 31 December 2024

-

1,238,049

37,500

1,275,549

At 31 December 2023

239,876

1,222,027

37,500

1,499,403

5.

Debtors: amounts falling due within one year

2024

2023

£

£

Trade debtors

17,962

-

Other debtors

7,101

16,140

25,063

16,140

6.

Creditors: amounts falling due within one year

2024

2023

£

£

Trade creditors

-

48

Amounts owed to group undertakings

-

15,000

Taxation and social security

3,561

-

3,561

15,048

7.	Called up share capital

Allotted, issued and fully paid:

Number:

Class:

Nominal

2024

2023

value:

£

£

121,011

Ordinary

1

121,011

121,011

8.	Related party disclosures

Bio-images Drug Delivery Ltd

G Crocker, a director of the company is also a director of Bio-images Drug Delivery Ltd. The company has an equity investment in Bio-images Drug Delivery Ltd held at a cost of £100,000 as at 31 December 2024 (2023: £100,000).